A cost-effectiveness evaluation of single and combined smoking cessation interventions in Texas.
Hill
Austin
A
Department of Management and Policy Sciences, The University of Texas Health Science Center at Houston School of Public Health, TX 77054, USA.
D000316:Adrenergic alpha-Agonists / Q000008:administration & dosage / Q000191:economics / Q000494:pharmacology; D000928:Antidepressive Agents / Q000008:administration & dosage / Q000191:economics / Q000494:pharmacology; D016642:Bupropion / Q000008:administration & dosage / Q000191:economics / Q000494:pharmacology; D003000:Clonidine / Q000008:administration & dosage / Q000191:economics / Q000494:pharmacology; D003362:Cost-Benefit Analysis; D003663:Decision Trees; D004359:Drug Therapy, Combination; D017048:Health Care Costs; D006801:Humans; D009538:Nicotine / Q000008:administration & dosage / Q000191:economics; D009661:Nortriptyline / Q000008:administration & dosage / Q000191:economics / Q000494:pharmacology; D012907:Smoking / Q000188:drug therapy*; D016540:Smoking Cessation / Q000191:economics* / Q000379:methods*; D013781:Texas; D014029:Tobacco Use Disorder / Q000188:drug therapy*; D016896:Treatment Outcome
D000316:Adrenergic alpha-Agonists; D000928:Antidepressive Agents; D016642:Bupropion; D009538:Nicotine; D009661:Nortriptyline; D003000:Clonidine